Clinical trial
A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)
NCT06806592 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double Blind, Randomised, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nerandomilast Over at Least 26 Weeks in Patients With Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases (SARD-ILD)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- September 13, 2025
- Completion date
- April 28, 2027
- Enrollment
- 414 (actual)
- Sites
- 153
Conditions
As the registry lists them; a condition with its own page is linked.
interstitial lung diseases, systemic autoimmune rheumatic diseases associated interstitial lung diseases